Immunocore Holdings (IMCR) Stock Overview
Engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IMCR from our risk checks.
IMCR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Immunocore Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.44 |
| 52 Week High | US$40.71 |
| 52 Week Low | US$23.15 |
| Beta | 0.82 |
| 1 Month Change | -8.46% |
| 3 Month Change | -18.52% |
| 1 Year Change | -0.47% |
| 3 Year Change | -40.45% |
| 5 Year Change | -27.40% |
| Change since IPO | -31.85% |
Recent News & Updates
Recent updates
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
Nov 08Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
Aug 02
Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Jun 10Immunocore Holdings: A Name On My Watch List
Apr 27Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet
Apr 26
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?
Mar 04Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Feb 27There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Jan 08Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Dec 10Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Oct 24Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Sep 19Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Aug 12Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Jul 24Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
Jun 16Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
May 11Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Apr 05Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
Jan 22Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Jan 21Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Dec 18Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S
May 08Shareholder Returns
| IMCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.6% | -0.7% | -1.9% |
| 1Y | -0.5% | 21.6% | 14.4% |
Return vs Industry: IMCR underperformed the US Biotechs industry which returned 23.9% over the past year.
Return vs Market: IMCR underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IMCR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMCR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 524 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME.
Immunocore Holdings plc Fundamentals Summary
| IMCR fundamental statistics | |
|---|---|
| Market cap | US$1.55b |
| Earnings (TTM) | -US$35.51m |
| Revenue (TTM) | US$400.02m |
Is IMCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMCR income statement (TTM) | |
|---|---|
| Revenue | US$400.02m |
| Cost of Revenue | US$13.86m |
| Gross Profit | US$386.15m |
| Other Expenses | US$421.67m |
| Earnings | -US$35.51m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 96.53% |
| Net Profit Margin | -8.88% |
| Debt/Equity Ratio | 103.2% |
How did IMCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 12:43 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immunocore Holdings plc is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |